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Trial DesignsTwelve weeks of treatment with empagliflozin
in patients with heart failure and reduced
ejection fraction: A double-blinded,
randomized, and placebo-controlled trial
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Morten Schou, MD, PhD a,l Herlev, Odense, København Roskilde, Aalborg and Copenhagen, DenmarkAims To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on N-terminal pro-b-type natriuretic
peptide (NT-proBNP) in patients with heart failure (HF) and reduced ejection fraction (HFrEF).
Methods and Results Empire HF was an investigator-initiated, multi-center, double-blinded, placebo-controlled,
randomized trial. Patients with mildly symptomatic HFrEF, mean (standard deviation (SD)) age 64 (11) years, 85% male, and
mean left ventricular ejection fraction 29% (8), on recommendedHF therapywere assigned to receive either empagliflozin 10mgonce
daily or placebo for 12 weeks. The primary endpoint was the between-group difference in the change of NT-proBNP from baseline to
12 weeks. In total, 95 patients were assigned to empagliflozin and 95 to placebo. No significant difference in the change of NT-
proBNPwith empagliflozin versus placebowas observed [Empagliflozin: baseline,median (interquartile range (IQR)) 582 (304-1020)
pg/mL, 12weeks, 478 (281-961) pg/mL; Placebo: baseline, 605 (322-1070) pg/mL, 12weeks, 520 (267-1075) pg/mL, adjusted
ratio of change empagliflozin/placebo 0.98; 95% confidence interval (CI) 0.82-1.11, P = 0.7]. Further, no significant difference was
observed in accelerometer-measured daily activity level [adjusted mean difference of change, empagliflozin versus placebo, -26.0
accelerometer counts; 95% CI -88.0 to 36.0, P = 0.4] or Kansas City Cardiomyopathy Questionnaire Overall Summary Score
[adjusted mean difference of change, empagliflozin versus placebo 0.8; 95% CI -2.3 to 3.9, P = 0.6].
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In type 2 diabetes (T2D), sodium-glucose co-transporter-2
(SGLT2) inhibitors reduce the risk of cardiovascular death or
hospitalization for heart failure (HF) with similar benefit in
patients with and without a history of HF.1-4 In the
Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure (DAPA-HF) trial, dapagliflozin reduced the
risk of cardiovascular death and worsening HF in patients
with established HF with reduced ejection fraction (HFrEF),
regardless of the presence of T2D.5,6 Furthermore, treat-
ment with dapagliflozin was associated with a reduction in
plasma concentrations of N-terminal pro-b-type natriuretic
peptide (NT-proBNP) after 8 months of treatment.5,6
However, in the Dapagliflozin Effects on Biomarkers,
Symptoms and Functional Status in Patients with HF with
Reduced Ejection Fraction (DEFINE-HF) trial, dapagliflozin
did not lower NT-proBNP in patients with HFrEF after 12
weeks of treatment.7 At present, it is unknown whether
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reduce NT-proBNP and improve clinical HF outcomes in
patients with HFrEF without T2D.8,9 In this randomized
placebo-controlled trial, we examined the effect of empagli-
flozin on NT-proBNP in patients with HFrEF.
Methods
Setting
The full studyprotocol haspreviously beenpublished.10 In
brief, the Empire HF trial was an investigator-initiated, multi-
center, double-blinded, placebo-controlled, randomized trial
assigning patients (1:1) to empagliflozin or placebo.
Recruitment took place between June 29, 2017, and
September 10, 2019, and the study ended on January 17,
2020, when 190 randomized patients had completed the
study as planned. The studywas independentlymonitored in
accordance with the Good Clinical Practice standards and
complies with the Declaration of Helsinki, the locally
appointed ethics committee approved the research protocol
and informed consent was obtained from the patients. The
manufacturer of empagliflozin had no part in the study.
Patients
The full list of inclusion and exclusion criteria is
presented in the Supplementary material, Section B.
Patients with New York Heart Association (NYHA)
functional class I-III symptoms and a left ventricular
ejection fraction (LVEF) of 40% or lower were recruited
from the participating HF outpatient clinics, with no
requirement to plasma concentrations of NT-proBNP at
screening or randomization. Treatment with stable
recommended HF therapy, and stable recommended
antidiabetic therapy in patients with T2D, was required at
least 30 days before randomization.
Randomization and blinding
Eligible patients were assessed at a screening visit and
entered a screening period where the baseline daily activity
level was assessed. All other procedures were performed at
the following baseline visit where eligible patients were
randomly assigned to treatment with empagliflozin or
matching placebo. The allocation sequence was generated
by the independent Glostrup Hospital Pharmacy using
computer-generated randomnumbers in blocks of 10without
stratification. Study investigators and patients were blinded to
treatment allocation for the duration of the study. Data
analyses were performed blinded to treatment allocation.
Procedures
After randomization, patients entered a 12-week
treatment period with empagliflozin 10 mg once daily
or placebo. Changes in background therapy were only
encouraged if side effects were suspected. The 12-week
procedures were performed at the end-of-study visit,
performed on day 90±15 days from the baseline visit.Plasma concentrations of NT-proBNP were analyzed on
fasting blood samples, which were immediately centri-
fuged upon collection and stored at -800C. A batch
analysis was performed in March 2020 at a central
laboratory blinded to treatment allocation (Atellica IM
NT-proBNP assay on Atellica IM analyzer platform,
Siemens Healthineers, Erlangen, Germany).11
Daily activity level was assessed using the Actigraph
wGT3X-BT accelerometer (Actigraph, Pensacola, FL).12
Patients were instructed to wear the accelerometer
around the waist continuously for 7 days, including
during sleep, and to remove the device only to avoid
contact with water. Daily activity level is reported in
accelerometer counts, with higher counts reflecting
higher daily activity level. Moreover, a subgroup of the
study population performed the 6-minute walk test
(Supplementary material, Section C).
Health status was quantified using the Kansas City
Cardiomyopathy Questionnaire (KCCQ).13 The KCCQ is
self-administered and consists of 23 items, summarized in
the Overall Summary Score (KCCQ-OSS), the Clinical
Summary Score (KCCQ-CSS), and the Total Symptom
Score (KCCQ-TSS). Scores range from 0 to 100, with
higher scores reflecting better health status. Patients
completed the questionnaire on their own before any
other procedures were performed. All adverse events
were reported by study investigators.
Endpoints
The primary endpoint was the between-group differ-
ence in the change of NT-proBNP from baseline to 12
weeks. Secondary endpoints included the between-group
difference in the change of daily activity level and health
status from baseline to 12 weeks. Exploratory endpoints
included the between-group difference in the change of
hematocrit, systolic blood pressure, body weight and
estimated glomerular filtration rate (eGFR) from baseline
to 12 weeks. Prespecified safety endpoints included
events of urinary tract infection, genital infection,
hypoglycemia, bone fracture, ketoacidosis, amputation,
Fournier’s gangrene, thromboembolic events, hospitali-
zations with volume depletion, and hospitalizations with
acute renal failure.
Statistical analysis
To test the primary hypothesis of a 30% (standard
deviation (SD) 70%) reduction in plasma concentrations
of NT-proBNP between the empagliflozin group and the
placebo group at 12 weeks, with a power of 0.80 and a
significance level of .05, a total sample size of 172 patients
randomly assigned to two groups was required. The
primary endpoint was log-transformed and analyzed
using a prespecified analysis of covariance (ANCOVA)
with the log-transformed plasma concentrations of NT-
proBNP, age, gender, history of T2D, and site of
randomization as baseline covariates. The primary
Figure 1
Flow diagram of the empire HF trial.
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population without imputation of missing values. Pre-
specified sensitivity analyses included analysis in the per-
protocol population and analysis in the ITT population
with missing NT-proBNP values imputed using multiple
imputations.14 Prespecified subgroup analyses were
performed for the primary endpoint, with P-values
adjusted using the method of Benjamini and Hochberg
which controls the false discovery rate (FDR). An
exploratory analysis comparing the proportion of pa-
tients with a reduction in NT-proBNP ≥30% was
performed using Fischer’s exact test.15
Secondary and exploratory continuous endpoints were
analyzed in prespecified ANCOVA models. Substantially
skewed endpoints were log-transformed prior to analysis.
Analysis of daily activity level was performed in a
modified ITT population, all other secondary and
exploratory analyses were performed in the ITT popula-
tion (Supplementary material, Sections C-E). An explor-
atory analysis comparing the proportion of patients with
≥5-point improvement or deterioration in the KCCQ-OSS
was performed using Fischer’s exact test.16 An explor-
atory analysis compared the 6-minute walking distance(6MWD) with the accelerometer-measured daily activity
level in simple linear regressions. Secondary and explor-
atory analyses were not adjusted for multiplicity.
Statistical testing was performed at a two-sided
significance level of 0.05 and estimates with their 95%
confidence intervals (CIs) were calculated. All analyses
were performed using R for Windows (version 3.6.1, R
Foundation for Statistical Computing, Vienna, Austria).
Unless stated otherwise, normally distributed continuous
data are presented as mean (SD), non-normally distribut-
ed as median (interquartile range (IQR)), and categorical
data as absolute numbers (%).Results
We assessed 697 patients for eligibility of whom 190
were eligible for randomization (Figure 1). Baseline
characteristics were similar in patients allocated to
empagliflozin and placebo (Table I). The randomized
patients were primarily males (85%), in NYHA functional
class II (78%) and 52% had one or more previous
hospitalizations for HF. Mean LVEF was 29%8 and plasma
concentration of NT-proBNP moderately elevated with a
Table I. Baseline characteristics of randomized patients
Empagliflozin (n = 95) Placebo (n = 95)
Age (years), median (IQR) 64 [57-73] 63 [55-72]
Male sex 79 (83) 83 (87)
BMI (kg/m2), median (IQR) 29 [27-33] 29 [26-33]
Caucasian 92 (97) 94 (99)
NYHA functional class
I 5 (5.3) 7 (7.4)
II 72 (76) 77 (81)
III 18 (19) 11 (12)
Heart rate/min, median (IQR) 68 [63-77] 70 [63-80]
Systolic blood pressure (mmHg),
median (IQR)
117 [107-130] 122 [109-132]
Peripheral edema 9 (9.5) 13 (14)
Jugular vein distension 0 (0.0) 1 (1.1)
LVEF (%), median (IQR) 30 [25-35] 30 [25-35]
NT-proBNP (pg/mL), median (IQR)
All (n = 190)
Sinus rhythm (n = 120)
Atrial fibrillation or flutter (n = 70)
582 (304-1020)
419 (277-672)
1050 (456-1845)
605 (322-1070)
452 (244-780)
993 (584-1480)
Primary cause of HF
Ischemic 48 (51) 49 (52)
Non-Ischemic 47 (49) 46 (48)
HF duration (months), median (IQR) 35 (12-67) 27 (13-62)
Number of HF hospitalizations
0 46 (48) 45 (47)
1 39 (41) 37 (39)
2≤ 10 (11) 13 (14)
T2D, history of or newly diagnosed 19 (20) 14 (15)
Newly diagnosed T2Da 8 (8.4) 1 (1.1)
HbA1c (mmol/mol), median (IQR) 40 (36-43) 39 (36-42)
Ischemic heart disease 50 (53) 53 (56)
Atrial fibrillation or flutter 36 (38) 34 (36)
Chronic kidney disease, stage 3 11 (12) 12 (13)
eGFR (mL/min/1.73m2), median (IQR) 73 [57-89] 74 [60-89]
CRTb 18 (19) 18 (19)
ICDc 45 (47) 46 (48)
ACE inhibitor, ARB or sacubitril-valsartan 90 (95) 92 (97)
Sacubitril-valsartan 31 (33) 27 (28)
Beta-blocker 91 (96) 89 (94)
MRA 62 (65) 63 (66)
Digitalis 2 (2.1) 2 (2.1)
Loop diuretic 62 (65) 59 (62)
Long-acting nitrates 4 (4.2) 5 (5.3)
Lipid lowering medicationd 60 (63) 65 (68)
Antithrombotic or anticoagulant medicatione 73 (77) 70 (74)
Antidiabetic medication
in patients with a history of T2D
n = 11 n = 13
Metformin 10 (91) 7 (54)
Sulfonylurea 2 (18) 1 (7.7)
DPP-4 inhibitor 0 (0.0) 5 (39)
GLP-1 receptor agonist 1 (9.1) 4 (31)
Insulin 5 (46) 3 (23)
Numbers are counts (%) unless stated otherwise. Both normally and non-normally distributed continuous variables are presented as median (IQR). IQR, interquartile range; BMI, body
mass index; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-b-type natriuretic peptide; HF, heart failure; T2D, type 2 diabetes;
Hba1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; ACE, angiotensin-
converting enzyme; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; DPP-4, Dipeptidyl peptidase 4; GLP-1, Glucagon-like peptide 1. aDefined as an
HbA1c equal to or above 48 mmol/mol at both screening and randomization in patients without a history of type 2 diabetes. bIncluding CRT with or without ICD. cIncluding ICD or CRT
with ICD. dIncluding statins, ezetemibe, fibrates, anion exchange resins and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. eIncluding acetylsalicylic acid (ASA),
Adenosine diphosphate (ADP) receptor blockers, vitamin K antagonist, Non-Vitamin K antagonist oral anticoagulants (NOACs), dipyridamole and others.
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18%, and atrial fibrillation or flutter in 37%. A high
proportion was on recommended HF therapy; 96% ofpatients were receiving an angiotensin-converting en-
zyme inhibitor, angiotensin receptor blocker, or
sacubitril-valsartan (31% sacubitril-valsartan); 96% were
Figure 2
A, NT-proBNP at baseline and 12 weeks, and the unadjusted relative treatment effect in the empagliflozin and placebo group with P-value from
the adjusted analysis. The whiskers represent 1.5 × IQR. B, Change in NT-proBNP in subgroups.All subgroups were prespecified, except patients
with AF or not. Median reported for all continuous variables. BMI, body mass index; NT-proBNP, N-terminal pro-b-type natriuretic peptide;
KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire Overall Summary Score; LVEF, left ventricular ejection fraction; eGFR, estimated
glomerular filtration rate; T2D, history of or newly diagnosed type 2 diabetes; AF, atrial fibrillation or flutter; CI, confidence interval. Unadjusted P-
value for interaction = 0.05 for NT-proBNP subgroups, all other unadjusted and FDR-adjusted P-values for interaction > 0.05.
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Figure 3
Daily activity level at baseline and 12 weeks, and the unadjusted absolute treatment effect in the empagliflozin and placebo group with P value
from the adjusted analysis. The whiskers represent 1.5 × IQR.
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ticoid receptor antagonist; 19% had a cardiac resynchro-
nization therapy (CRT) device and 48% had an
implantable cardioverter-defibrillator (ICD). The median
adherence rate to the allocated treatment was 100% (98.9-
100) (Supplementary material, Section F). A total of 44
(23%) of the included patients with sinus rhythm and 40
(21%) with atrial fibrillation or flutter had fulfilled the
criteria for inclusion in the DAPA-HF trial.
NT-proBNP
The 12-week visit was missed in 2 patients due to
causes unrelated to the study, and 2 patients had blood
samples which could not be analyzed (Figure 1). In total,
94 in the empagliflozin group and 92 in the placebo
group were included in the analysis. The primary
endpoint, the between-group difference in the change
of NT-proBNP from baseline to 12 weeks was not
significant [Empagliflozin: baseline, median (IQR) 582
(304-1020) pg/mL, 12 weeks, 478 (281-961) pg/mL;
Placebo: baseline, 605 (322-1070) pg/mL, 12 weeks,
520 (267-1075) pg/mL with adjusted ratio of change
empagliflozin/placebo 0.98; 95% confidence interval (CI)0.82-1.11, P = .7] (Figure 2a). NT-proBNP did not change
significantly over time in neither the empagliflozin (P =
.1) nor in the placebo group (P = .2). Analysis of the
primary endpoint in the ITT population with imputation
and analysis in the per-protocol population yielded
similar results [all P = .7]. The results were consistent
within the prespecified subgroups, except of a trend
towards an effect in patients with NT-proBNP ≥591 pg/L
[adjusted ratio of change empagliflozin/placebo 0.81; 95%CI
0.54-1.04, unadjusted P-value for interaction = .05 (FDR-
adjusted P = .5)] (Figure 2b). In the exploratory analysis, a
reduction in NT-proBNP ≥30% was observed in 27 of 94
patients (29%) in the empagliflozin group and 18 of 92
patients (20%) in the placebo group, with no significant
between-group difference [empagliflozin versus placebo
odds ratio (OR) 1.66; 95% CI 0.84-3.28, P = .2].
Daily activity level
The baseline or the 12-week activity measurement was
missed in 17 patients due to logistic problems or
technical issues with the accelerometer, and 7 patients
had inadequate accelerometer data with less than 4 valid
days. In total, 82 in the empagliflozin group and 84 in the
Figure 4
KCCQ-OSS score at baseline and 12 weeks, and the unadjusted absolute treatment effect in the empagliflozin and placebo group with P-value
from the adjusted analysis. The whiskers represent 1.5 × IQR.
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secondary endpoint, the between-group difference in
the change of daily activity level in the empagliflozin
group compared with the placebo was not significant
[Empagliflozin: baseline, mean (SD) 1365 (391) acceler-
ometer counts, 12 weeks, 1310 (324) accelerometer
counts; Placebo: baseline, 1335 (370) accelerometer
counts, 12 weeks, 1330 (358) accelerometer counts
with adjusted mean difference of change empagliflozin
versus placebo -26.0 accelerometer counts; 95% CI -88.0
to 36.0, P = .4] (Figure 3). In an exploratory analysis, a
significant association between the 6MWD and the
accelerometer-measured daily activity level was observed
in a representative subgroup of the study population
(Supplementary material, Section C).
Health status
In total, 94 in the empagliflozin group and 92 in the
placebo group completed KCCQ at both visits. The
between-group difference in KCCQ-OSS was not signifi-
cant [Empagliflozin: baseline, mean (SD) 75.6 (18.3), 12
weeks, 77.6 (17.6). Placebo: baseline, 74.9 (17.8), 12
weeks, 76.8 (19.8) with adjusted mean difference ofchange empagliflozin versus placebo 0.8; 95% CI -2.3 to
3.9, P = .6] (Figure 4). Similar results were observed for
KCCQ-CSS and KCCQ-TSS (Supplementary material,
Section D). In the exploratory analysis, improvement in
KCCQ-OSS≥5 was observed in 40 of 94 patients (43%) in
the empagliflozin group and 39 of 92 patients (42%) in the
placebo group, with no significant between-group
difference [Empagliflozin versus placebo odds ratio
(OR) 1.01; 95% CI 0.56-1.80, P = 1.0]. A deterioration in
KCCQ-OSS≥5 was observed in 20 of 94 patients (21%) in
the empagliflozin group and 16 of 92 patients (17%) in the
placebo group, with no significant between-group
difference [empagliflozin versus placebo OR 1.28; 95%
CI 0.62-2.67, P = .6].
Supplementary analyses
In prespecified exploratory analyses, significant differ-
ences in the change of hematocrit, systolic blood
pressure and body weight with empagliflozin versus
placebo were observed, with an increase in hematocrit,
and decreases in systolic blood pressure and body weight.
No significant difference in the change of eGFR was
observed (Supplementary material, Section E).
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A summary of prespecified safety endpoints, hospital-
izations for HF and deaths during the on-treatment period
is presented in the Supplementary material, Section G. In
total, 11 patients were hospitalized, and no patients died
during the study. Observed frequencies were too low to
allow for statistical analysis of differences between
allocated groups. No adverse events led to treatment
discontinuation.
Discussion
Main findings
In low-risk patients with HFrEF with mild symptoms on
recommendedHF therapy, empagliflozin did not changeNT-
proBNP after 12 weeks. Further, no change in daily activity
level or health status was observed with empagliflozin.
The Empagliflozin, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
trial in patients with T2D and established cardiovascular
disease demonstrated a significant reduction in cardio-
vascular death or hospitalization for HF in patients with
or without investigator-reported HF, a benefit observed
within few months of initiating treatment with empagli-
flozin.2,17 This prompt treatment effect, could suggest an
underlying hemodynamic mechanism, including a lower-
ing of intracardiac pressures.18,19 A reduction of filling
pressures would be anticipated to be associated with an
early decrease in plasma concentrations of NT-proBNP.
Based on this, we hypothesized in the Empire HF trial that
12 weeks of treatment with empagliflozin would reduce
NT-proBNP in patients with established HFrEF on
recommended HF therapy. However, in accordance
with the results from the DEFINE-HF and the Effects of
Empagliflozin on Cardiac Structure in Patients with Type
2 Diabetes (EMPA-HEART Cardiolink-6) trials,7,8 we did
not observe this early effect on plasma concentrations of
NT-proBNP after initiation of treatment with an SGLT2
inhibitor.
Compared with the DAPA-HF and DEFINE-HF trials,5 ,7
the Empire HF trial included a larger proportion of
Caucasian males, and patients with better functional
capacity as well as lower plasma concentrations of NT-
proBNP. Further, a lower proportion of the patients had
T2D and a lower proportion was treated with a loop
diuretic or digitalis. Both the Empire HF and DEFINE-HF
trials had a higher proportion of patients treated with
sacubitril-valsartan, a CRT and/or an ICD device than the
DAPA-HF trial. These differences suggest that patients
included in the Empire HF trial were well-treated with
recommended HF therapy, had mild symptoms, and a
relatively low-risk for cardiovascular events estimated by
the plasma concentrations of NT-proBNP.20 Thus, it
could be speculated that the current study included
patients where additional treatment effects were difficult
to obtain. However, subgroup analyses showed anapparently larger effect in patients with NT-proBNP ≥591
pg/mL (median ≈ DAPA-HF inclusion criteria) than in
patients with NT-proBNP below the median (Figure 2b).
Whether this observation reflects a true effect of empagli-
flozin on NT-proBNP already after 12 weeks in patients with
NT-proBNP ≥591 pg/mL remains to be determined. We
believe the present study population is representative of an
important proportion of patients with HFrEF in everyday
clinical practice. Increased plasma concentrations of NT-
proBNPwere not an inclusion criterion in the present trial. It
may explain why plasma concentrations of NT-proBNP are
lower than the ones observed in e.g. the DAPA-HF trial and
the patients included in the present trial may primarily
represent the best 1/3 of contemporarily treated patients
with HFrEF.21
Due to the lack of effect of empagliflozin 10 mg on
plasma concentrations of NT-proBNP, it may be specu-
lated that either the patient adherence was poor or that
the dose of empagliflozin was too low for patients
without T2D. However, during monitoring of the study,
no poor adherence was observed, and in prespecified
exploratory analyses, a significant treatment effect on
hematocrit, systolic blood pressure, and body weight was
observed (Supplementary material, Section E).6 ,17 There-
fore, poor patient adherence to treatment or inadequate
dosing of empagliflozin are probably not reasons for the
lack of effect on NT-proBNP.
In contrast with the present study, the DAPA-HF trial, a
20% reduction in NT-proBNP after 8 months was
observed.5 Therefore, it may be proposed that the
chosen treatment period was to short or that only
dapagliflozin, and not empagliflozin, reduces NT-
proBNP. However, in the DEFINE-HF trial,7 no effect of
dapagliflozin on NT-proBNP was observed after 12 weeks
in HFrEF patients with a median NT-proBNP of 1136 pg/
mL, which supports that no difference exists between
dapagliflozin and empagliflozin for the effect on natri-
uretic peptides. The effect on NT-proBNP after a longer
treatment period in the DAPA-HF trial is in contrast with
the prompt effect of SGLT2 inhibitors on clinical HF
outcomes.1,5 This may be explained by counteracting
stimuli on NT-proBNP during treatment with SGLT2
inhibitors. An increase in hematocrit may reflect a
diuretic effect and a decrease in systolic blood pressure
a reduction in afterload which together induce a decrease
in NT-proBNP release,22 versus a small decline in eGFR
and body weight which may oppose this effect, probably
by a decrease in clearance of NT-proBNP.6,23,24
Considering the results of the DAPA-HF trial,5,25 which
demonstrated an effect of an SGLT2 inhibitor on
mortality, morbidity and health status (true clinical
endpoints) in patients with HFrEF,5 ,25 it may be
proposed that we chose the wrong endpoint (surrogate)
in the Empire HF trial. Our results, therefore, re-
emphasize the complexity of selecting the right surrogate
endpoint in HF trials.26 The observed effects in the
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and body weight suggest that 10 mg of empagliflozin has
metabolic and hemodynamic effects even in mildly
symptomatic HFrEF patients with a lower risk of
clinical HF outcomes than the patients included in the
DAPA-HF trial.5
No change in daily activity level assessed by
accelerometry or health status assessed by KCCQ was
observed in the Empire HF trial. In that framework, it
should be noted that the health status at baseline was
better compared with both the DEFINE-HF and DAPA-
HF trials across the KCCQ scores,7 ,25 emphasizing that
further improvements were less likely to occur.
Activity level assessed by accelerometry is a relatively
new endpoint in clinical HF trials,27 for which reason
we evaluated it against the 6-minute walk test.28 There
was a clear association between the 6MWD and the
accelerometer-measured daily activity level, suggesting
that the accelerometer detect a meaningful physiolog-
ical measure for HF research (Supplementary material,
Section C).
Methodological considerations
The generalizability of our findings needs to be
discussed. The results should not be extrapolated to
patients with HFrEF and higher plasma concentrations of
NT-proBNP and/or who are more symptomatic. Based on
the presented data, and the results from other studies
including patients with T2D and cardiovascular disease,
or HFrEF patients with more symptoms and a worse
health status,7,8 the effect of 12 weeks treatment with
empagliflozin on plasma concentrations of NT-proBNP is
probably less than 30% and a longer treatment period is
likely needed to observe an eventually smaller effect on
NT-proBNP.
Clinical perspectives
The results of the Empire HF trial (and DEFINE-HF)
indicate that plasma concentrations of NT-proBNP do not
necessarily decrease despite initiation of a treatment that
reduces morbidity and mortality. Clinicians should be
aware of this to guide their patients sufficiently.
Moreover, considering the results of the DEFINE-HF trial
and the present study, it is likely that the observed clinical
benefits of SGLT2 inhibitors are not mediated by an initial
decrease in NT-proBNP in HFrEF patients with and
without T2D. Finally, in patients not fulfilling the
inclusion criteria of the DAPA-HF trial according to
functional class and NT-proBNP, it may be speculated that
an SGLT2 inhibitor does not rapidly improve symptoms
and quality of life.
In conclusion, empagliflozin 10 mg once daily did not
change NT-proBNP after 12 weeks in low-risk patients
with HFrEF with mild symptoms receiving recommended
HF therapy. Further, no change in daily activity level or
health status was observed.Acknowledgements
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